182 related articles for article (PubMed ID: 30723502)
21. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).
Tan BS; Tiong KH; Choo HL; Chung FF; Hii LW; Tan SH; Yap IK; Pani S; Khor NT; Wong SF; Rosli R; Cheong SK; Leong CO
Cell Death Dis; 2015 Jul; 6(7):e1826. PubMed ID: 26181206
[TBL] [Abstract][Full Text] [Related]
22. Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl.
Vaughan CA; Singh S; Windle B; Yeudall WA; Frum R; Grossman SR; Deb SP; Deb S
Genes Cancer; 2012 Jul; 3(7-8):491-502. PubMed ID: 23264849
[TBL] [Abstract][Full Text] [Related]
23. The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC.
Cai Y; Yan X; Zhang G; Zhao W; Jiao S
Oncotarget; 2015 Aug; 6(22):18997-9005. PubMed ID: 25944617
[TBL] [Abstract][Full Text] [Related]
24. Modulation of wild-type p53 activity by mutant p53 R273H depends on the p53 responsive element (p53RE). A comparative study between the p53REs of the MDM2, WAFI/Cip1 and Bax genes in the lung cancer environment. WAFI/Cip1 = WAF1/Cip1.
Zacharatos PV; Gorgoulis VG; Kotsinas A; Manolis EN; Liloglou T; Rassidakis AN; Kanavaros P; Field JD; Halazonetis T; Kittas C
Anticancer Res; 1999; 19(1A):579-87. PubMed ID: 10226602
[TBL] [Abstract][Full Text] [Related]
25. Verteporfin disrupts multiple steps of autophagy and regulates p53 to sensitize osteosarcoma cells.
Saini H; Sharma H; Mukherjee S; Chowdhury S; Chowdhury R
Cancer Cell Int; 2021 Jan; 21(1):52. PubMed ID: 33446200
[TBL] [Abstract][Full Text] [Related]
26. Deficient or R273H and R248W Mutations of p53 Promote Chemoresistance to 5-FU
Gao X; Zheng X; Zhang Y; Dong L; Sun L; Zhao N; Ding C; Ma Z; Wang Y
Front Cell Dev Biol; 2021; 9():788331. PubMed ID: 35071232
[No Abstract] [Full Text] [Related]
27. Yet another function of p53--the switch that determines whether radiation-induced autophagy will be cytoprotective or nonprotective: implications for autophagy inhibition as a therapeutic strategy.
Chakradeo S; Sharma K; Alhaddad A; Bakhshwin D; Le N; Harada H; Nakajima W; Yeudall WA; Torti SV; Torti FM; Gewirtz DA
Mol Pharmacol; 2015 May; 87(5):803-14. PubMed ID: 25667224
[TBL] [Abstract][Full Text] [Related]
28. Triangular Relationship between p53, Autophagy, and Chemotherapy Resistance.
Xu J; Patel NH; Gewirtz DA
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33256191
[TBL] [Abstract][Full Text] [Related]
29. Molecular interplay between mutant p53 proteins and autophagy in cancer cells.
Cordani M; Butera G; Pacchiana R; Donadelli M
Biochim Biophys Acta Rev Cancer; 2017 Jan; 1867(1):19-28. PubMed ID: 27871965
[TBL] [Abstract][Full Text] [Related]
30. Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells.
Circu M; Cardelli J; Barr MP; O'Byrne K; Mills G; El-Osta H
PLoS One; 2017; 12(9):e0184922. PubMed ID: 28945807
[TBL] [Abstract][Full Text] [Related]
31. Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches.
Alvarado-Ortiz E; de la Cruz-López KG; Becerril-Rico J; Sarabia-Sánchez MA; Ortiz-Sánchez E; García-Carrancá A
Front Cell Dev Biol; 2020; 8():607670. PubMed ID: 33644030
[TBL] [Abstract][Full Text] [Related]
32. Proteasome inhibition paradoxically degrades gain-of-function mutant p53 R273H in NSCLC and could have therapeutic implications.
Oduah EI; Sharfstein ST; Seetharamu N; Grossman SR; Litovchick L
Front Oncol; 2024; 14():1363543. PubMed ID: 38660140
[TBL] [Abstract][Full Text] [Related]
33. Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells.
Yoshikawa K; Hamada J; Tada M; Kameyama T; Nakagawa K; Suzuki Y; Ikawa M; Hassan NM; Kitagawa Y; Moriuchi T
Biomed Res; 2010 Dec; 31(6):401-11. PubMed ID: 21187651
[TBL] [Abstract][Full Text] [Related]
34. An insight into the mechanistic role of p53-mediated autophagy induction in response to proteasomal inhibition-induced neurotoxicity.
Du Y; Yang D; Li L; Luo G; Li T; Fan X; Wang Q; Zhang X; Wang Y; Le W
Autophagy; 2009 Jul; 5(5):663-75. PubMed ID: 19337030
[TBL] [Abstract][Full Text] [Related]
35. Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity.
Ellison V; Annor GK; Freedman C; Xiao G; Lundine D; Freulich E; Prives C; Bargonetti J
Oncotarget; 2021 Jun; 12(12):1128-1146. PubMed ID: 34136083
[TBL] [Abstract][Full Text] [Related]
36. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
[TBL] [Abstract][Full Text] [Related]
37. Induction of autophagy counteracts the anticancer effect of cisplatin in human esophageal cancer cells with acquired drug resistance.
Yu L; Gu C; Zhong D; Shi L; Kong Y; Zhou Z; Liu S
Cancer Lett; 2014 Dec; 355(1):34-45. PubMed ID: 25236911
[TBL] [Abstract][Full Text] [Related]
38. p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo.
Alexandrova EM; Mirza SA; Xu S; Schulz-Heddergott R; Marchenko ND; Moll UM
Cell Death Dis; 2017 Mar; 8(3):e2661. PubMed ID: 28277540
[TBL] [Abstract][Full Text] [Related]
39. Reactivation of mutant p53 by capsaicin, the major constituent of peppers.
Garufi A; Pistritto G; Cirone M; D'Orazi G
J Exp Clin Cancer Res; 2016 Sep; 35(1):136. PubMed ID: 27599722
[TBL] [Abstract][Full Text] [Related]
40. Mutant p53 - Heat Shock Response Oncogenic Cooperation: A New Mechanism of Cancer Cell Survival.
Alexandrova EM; Marchenko ND
Front Endocrinol (Lausanne); 2015; 6():53. PubMed ID: 25954247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
